BioXcel Therapeutics (BTAI) Common Equity (2017 - 2026)

BioXcel Therapeutics' Common Equity history runs 10 years deep, the most recent figure standing at -$105.5 million for Q1 2026.

• In Q1 2026, Common Equity fell 17.05% year-over-year to -$105.5 million; the TTM figure through Mar 2026 stood at -$105.5 million (down 17.05% YoY), while the FY2025 annual figure was -$95.5 million, down 2.54% from the prior year.
• Common Equity was -$105.5 million for Q1 2026 at BioXcel Therapeutics, down from -$95.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $194.0 million in Q1 2022 to a low of -$107.7 million in Q2 2025.
• Historically, Common Equity has averaged -$17.0 million across 5 years, with a median of -$72.4 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Common Equity climbed 3.9% in 2022, then slumped 1367.07% in 2024.
• A 5-year view of Common Equity shows it stood at $76.8 million in 2022, then sank by 173.6% to -$56.5 million in 2023, then tumbled by 64.76% to -$93.1 million in 2024, then fell by 2.54% to -$95.5 million in 2025, then decreased by 10.56% to -$105.5 million in 2026.
• The last three Common Equity figures came in at -$105.5 million (Q1 2026), -$95.5 million (Q4 2025), and -$88.9 million (Q3 2025), per Business Quant data.